Du är här

2015-09-22

Quantum Genomics: Quantum Genomics to meet investors at the European Large & Midcap Event, October 7 & 8, 2015

Quantum Genomics (Alternext - FR0011648971 - ALQGC)
, a biopharmaceutical company with the mission of developing new therapies for
unmet medical needs in the field of cardiovascular diseases, will be
participating at the 15thedition of theEuropean
Large&Midcap Event
, a conference dedicated to meetings between European listed companies and
institutional investors, to be held in Paris on October 7&8, 2015.

On that occasion,Lionel Ségard
, Chairman and CEO of Quantum Genomics, andMarc Karako
, Chief Financial Officer, will comment on the Company's latest progress, in
particular the Phase IIa clinical trials currently under way for high blood
pressure of its drug candidate QGC001 and in preparation stage for the
treatment of heart failure.

QGC001 is the first of a new class of therapeutics for the treatment of
complicated/resistant hypertension, called Brain Aminopeptidase A Inhibitors
(BAPAIs). The objective of QGC001 is to offer an alternative therapy for the
treatment of high blood pressure, aimed particularly at patients with a Low
Renin High Vasopressin (LRHV) hormonal profile.

------------------------------------------------------------------------------------------------------------------
| CONTACTS ABOUT QUANTUM GENOMICS |
| |
| |
|Quantum Genomics Quantum Genomics is a biopharmaceutical company with the mission of developing |
| new therapies for unmet medical needs in the field of cardiovascular |
|Lionel Ségard diseases, especially high blood pressure and heart failure. |
|Chairman&Chief Executive Officer |
|+33 1 85 34 77 77 Quantum Genomics is developing a new therapeutic approach based on BAPAI |
| (Brain Aminopeptidase A Inhibition). This is the result of more than 20 |
|Quantum Genomics years of academic research in the laboratories of the Collège de France, |
| INSERM, CNRS and the University of Paris Descartes. |
|Marc Karako |
|CFO - Investor Relations Quantum Genomics is listed on the Alternext market in Paris (ISIN code |
|+33 1 85 34 77 75 FR0011648971, Ticker ALQGC). |
|marc.karako@quantum-genomics.com |
| |
| |
|ACTUS finance&communication |
| |
|Jean-Michel Marmillon |
|Press Relations |
|+33 1 53 67 36 73 |
|jmmarmillon@actus.fr |
------------------------------------------------------------------------------------------------------------------

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Quantum Genomics via Globenewswire

HUG#1953569

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.